The Ibogaine Dossier
The Ibogaine Dossier

NYU Conference on Ibogaine Nov 5-6, 1999

Search the Web!

iboga fruit
variety iboga fruit

Main | Search | Science | Opinion | Literature | Links | Treatment | Bookshop | Feedback
The Ibogaine Dossier


Michael Bosman
Editor, The Ibogaine Dossier (retired)

Revised August 26, 2001
Howard S. Lotsof
Ibogaine Consultant

Concern has been expressed regarding ibogaine neurotoxicity.

However, an intra-peritoneal dose of 40 mg/kg for 12 days, or 10 mg/kg for 30 days caused no significant pathologic findings in rat heart, liver, kidneys, and brain. (Dhahir 1971) No neurotoxicity was observed after 5-25 mg/kg ibogaine for 4 days per os in African green monkeys. (Sanchez-Ramos 1994)

While O'Hearn and Molliver describe that ibogaine and harmaline have selective neurotoxic effects, leading to degeneration of Purkinje cells in the cerebellar vermis, (O'Hearn 1993a, 1993b) Molinari et al. subsequently report that ibogaine induced neurotoxicity is dose-dependent, not causing pathological changes at therapeutic doses in the rat. (Molinari 1996)

Glick shows that 18-methoxy-coronaridine, a novel, synthetic iboga alkaloid congener, mimics ibogaine's effects on drug self-administration without evidence of cerebellar toxicity at a high dose (100 mg/kg). (Glick 1996) Popik states that ibogaine exhibits neuroprotective properties in cultures of cerebellar granule cell neurons. (Popik 1995)

Further, to the matter of neurotoxicity, Helsley shows no significant differences in Purkinje cell numbers between ibogaine and control groups (Helsley 1997) while Xu in work jointly performed at the University of Arkansas for Medical Sciences and the Division of Neurotoxicology, National Center for Toxicological Research, an FDA laboratory showed no neurotoxicity above controls at human therapeutic doses of 25 mg/kg of ibogaine in the rat. (Xu 2000)


  1. Methods for the detection and determination of ibogaine in biological materials. Dhahir, H.I., Jain, N.C. and Forney, R.B. J Forensic Sci 16:103-108, 1971.
  2. Ibogaine research update: phase I human study. Sanchez-Ramos, J. and Mash, D.C. Multidisciplinary Association for Psychedelic Studies 4:11, 1994.
  3. Ibogaine induces glial activation in parasagittal zones of the cerebellum. O'Hearn, E., Long, D.B. and Molliver, M.E. Neuroreport 4:299-302, 1993.
  4. Degeneration of Purkinje cells in parasagittal zones of the cerebellar vermis after treatment with ibogaine or harmaline. O'Hearn, E. and Molliver, M.E. Neuroscience 55:303-310, 1993.
  5. Ibogaine neurotoxicity: a re-evaluation. Molinari, H.H., Maisonneuve, I.M. and Glick, S.D. Brain Res 737:255-262, 1996.
  6. 18 Methoxycoronaridine, a Nontoxic Iboga Alkaloid Congener: Effects on Morphine and Cocaine Self Administration and on Mesolimbic Dopamine Release in Rats. Glick, S.D., Kuehne, M.E., Maisonneuve, I.M., Bandarage, U.K. and Molinari, H.H. Brain Res 719:29-35, 1996.
  7. NMDA Antagonist Properties of the Putative Antiaddictive Drug, Ibogaine. Popik, P., Layer, R.T., Fossom, L.H., et al. J Pharmacol Exp Ther 275:753-760, 1995.
  8. Effects of Chronic Ibogaine Treatment on Cerebellar Purkinje Cells in the Rat. Helsley, S., Dlugos C.A., Pentney R.J., Rabin R.A., Winter J.C. Brain Reseach 759(2):306-308, 1997.
  9. A Dose-Response Study of Ibogaine-Induced Neuropathology in the Rat Cerelellum. Xu Z., Chang L.W., Slikker W. Jr., Ali S.F., Rountee R.L., Scallet A.C. Toxicol Sci 57(1):95-101,2000.

Top of page | Main | Search | Science | Opinion | Literature | Links | Treatment | Bookshop | Feedback

ibogaine molecule

Tabernanthe iboga © 1999
The Ibogaine Dossier